Personalized Melanoma Treatment Platforms

This inventive concept envisions a next-generation melanoma treatment paradigm, integrating dapansutrile-based pharmaceutical compositions with advanced technologies, such as wearable devices, genomic analysis, and machine learning algorithms, to provide personalized and adaptive treatment plans, improving treatment outcomes and patient care.

The original patent disclosed methods for treating melanoma using dapansutrile. However, these methods are limited by their lack of personalization, inability to adapt to real-time biomarker analysis, and limited understanding of the genetic profile of patients. This inventive concept addresses these limitations by proposing a comprehensive treatment platform that combines dapansutrile with cutting-edge technologies to provide tailored treatment plans, thereby improving treatment efficacy and reducing adverse effects.

The inventive concept comprises four key components: (1) a dapansutrile-based pharmaceutical composition, (2) a wearable device for real-time biomarker analysis and adaptive administration, (3) a genomic analysis platform for generating personalized treatment plans based on genetic profiles, and (4) a machine learning algorithm for predicting treatment outcomes and detecting early signs of melanoma recurrence or resistance. The combination therapy of dapansutrile and an immune checkpoint inhibitor, along with a nanoparticle-based delivery system, enables targeted and sustained release of the therapy. Additionally, the portable optical imaging system and machine learning algorithm facilitate non-invasive melanoma monitoring, while the personalized melanoma vaccine leverages dapansutrile-treated dendritic cells and customized tumor antigens to enhance treatment efficacy.

The inventive concept's novelty lies in its integration of dapansutrile with advanced technologies to provide personalized and adaptive treatment plans, which is a significant departure from the original patent's methods. The inventive step resides in the combination of these technologies to create a comprehensive treatment platform that addresses the limitations of the original patent.

Alternative embodiments of the inventive concept could include the use of different pharmaceutical compositions, varying wearable device designs, or alternative genomic analysis platforms. Additionally, the inventive concept could be adapted for use in treating other types of cancer, leveraging the versatility of dapansutrile and the advanced technologies employed.

The inventive concept has significant commercial potential in the melanoma treatment market, estimated to reach $12.4 billion by 2025. The platform's ability to provide personalized and adaptive treatment plans, improving treatment outcomes and patient care, positions it for widespread adoption in the pharmaceutical and biotechnology industries.